Cue Biopharma raises $50 million in private placement of stock and warrants

Cue Biopharma, Inc. (Nasdaq: CUE) announced on July 9, 2026 that it had entered a securities purchase agreement for a private placement raising approximately $50.0 million. The deal covers 1,418,071 shares of common stock at $33.21 per share, plus pre-funded warrants for up to 87,500 shares at $33.209 per warrant.¹

The placement is expected to close on or about July 13, 2026, subject to customary closing conditions, and the pre-funded warrants carry an exercise price of $0.001 per share, are immediately exercisable, and remain exercisable until fully exercised.¹

Cormorant Asset Management led the round, and Columbia Threadneedle Investments was among the new investment funds that participated.¹ Cue said it plans to use the net proceeds to further fund clinical development and for other general corporate purposes.¹

CEO Shao-Lee Lin commented on the financing and pointed to an upcoming data readout. She said the company is looking forward to clinical milestones including results from Ascendant Health's ongoing Phase 2 study of chronic spontaneous urticaria (CSU) in China, expected by the end of the third quarter of 2026.¹

The securities were not registered under the Securities Act. They have not been registered under the Securities Act of 1933, and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption.¹ Separately, Cue agreed to file a resale registration statement with the SEC within 30 days of the closing.¹

Also on July 9, 2026, Cue's board granted RSU awards under its 2026 Stock Incentive Plan. The board approved an aggregate 1,064,492 restricted stock units to employees and executives, with CEO Shao-Lee Lin receiving 655,074 RSUs, Chief Legal and Compliance Officer Sumita Ray receiving 109,178 RSUs, and Principal Accounting Officer Michael Meluzio receiving 81,884 RSUs.¹